Patent US4902615A successfully refreshed from Google Patents.
US4902615A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Detection of human cancer cells with antibodies to human cancer nucleolar antigen p120
Assignee: BIOSCIENCES Corp OF TEXAS 4900 FANNIN HOUSTON TEXAS 77004 A CORP OF DE
•
Filing: 1987-03-27
•
Granted: 1990-02-20
•
Expires: 2007-03-27
Abstract
Abstract Tumor nucleoli were treated with polyclonal antisera to normal human tissue nucleoli to block determinants common to tumor and normal tissue nucleoli. Immunization of mice with these immune-complexes resulted in the development of a monoclonal antibody (FB2) to a novel nucleolar proliferation associated antigen which has a molecular wei The present invention was made with partial support from Federal funding grants. Subject to these grants, the Government may exercise certain rights in the invention.
Inventors
- 👤 James W. Freeman
- 👤 Harris Busch
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 20:30
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/975; Y10S436/00; Y10S436/807; Y10S436/808; Y10S436/811; Y10S436/813
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
76 words
A human cancer cell associated nucleolar antigen substantially in purified form characterized by: a pI on isoelectrofocusing of about 4.1 to about 4.8; a molecular weight of about 120,000±5,000 daltons as measured by polyacrylamide gel electrophoresis; being primarily localized in nucleoli of human cancer cells, but not detected in normal, non-proliferating cells; being expressed in the early G 1 cell cycle phase; and having a binding specificity to antibody derived from hybridoma ATCC HB 9346 deposit.
Claim 2
Dependent Claim
76 words
A human cancer cell associated nucleolar antigen substantially in purified form characterized by: a pI on isoelectrofocusing of about 4.1 to about 4.8; a molecular weight of about 120,000±5,000 daltons as measured by polyacrylamide gel electrophoresis; being primarily localized in nucleoli of human cancer cells, but not detected in normal, non-proliferating cells; being expressed in the early G 1 cell cycle phase; and having a binding specificity to antibody derived from hybridoma ATCC HB 9346 deposit.
Claim 3
Dependent Claim
77 words
Antibody having binding specificity to nucleolar antigen p120, which nucleolar antigen is characterized by: a pI on isoelectrofocusing of about 4.1 to about 4.8; a molecular weight of about 120,000±5,000 daltons as measured by polyacrylamide gel electrophoresis; being primarily localized in nucleoli of human cancer cells, but not detected in normal, non-proliferating cells; being expressed in the early G 1 cell cycle phase; and having a binding specificity to antibody derived from hybridoma ATCC HB 9346 deposit.
Claim 4
Dependent Claim
77 words
Antibody having binding specificity to nucleolar antigen p120, which nucleolar antigen is characterized by: a pI on isoelectrofocusing of about 4.1 to about 4.8; a molecular weight of about 120,000±5,000 daltons as measured by polyacrylamide gel electrophoresis; being primarily localized in nucleoli of human cancer cells, but not detected in normal, non-proliferating cells; being expressed in the early G 1 cell cycle phase; and having a binding specificity to antibody derived from hybridoma ATCC HB 9346 deposit.
Claim 5
Dependent Claim
10 words
The antibody of claim 2 which is a monoclonal antibody.
Claim 6
Dependent Claim
16 words
The antibody of claim 2 which is derived from continuous cell line ATCC HB 9346 deposit.
Claim 7
Dependent Claim
15 words
The antibody of claim 2 which has been produced with nucleoli isolated from HeLa cells.
Claim 8
Dependent Claim
85 words
A continuous cell line which produces a monoclonal antibody having binding specificity to nucleolar antigen p120, which nucleolar antigen is characterized by: a pI on isoelectrofocusing of about 4.1 to about 4.8; a molecular weight of about 120,000±5,000 daltons as measured by polyacrylamide gel electrophoresis; being primarily localized in nucleoli of human cancer cells, but not detected in normal, non-proliferating cells; being expressed in the early G 1 cell cycle phase; and having a binding specificity to antibody derived from hybridoma ATCC HB 9346 deposit.
Claim 9
Dependent Claim
85 words
A continuous cell line which produces a monoclonal antibody having binding specificity to nucleolar antigen p120, which nucleolar antigen is characterized by: a pI on isoelectrofocusing of about 4.1 to about 4.8; a molecular weight of about 120,000±5,000 daltons as measured by polyacrylamide gel electrophoresis; being primarily localized in nucleoli of human cancer cells, but not detected in normal, non-proliferating cells; being expressed in the early G 1 cell cycle phase; and having a binding specificity to antibody derived from hybridoma ATCC HB 9346 deposit.
Claim 10
Dependent Claim
16 words
The continuous cell line of claim 6 which is a clone of ATCC HB 9346 deposit.
Claim 11
Dependent Claim
52 words
A process for the immunological detection of cancer in human tissue or cell specimens comprising: contacting specimens with antibody characterized by binding specificity to nucleolar antigen p120 and detecting the localization of said antibody in the nucleoli of malignant cells but not normal cells of said specimen as a measure of cancer.
Claim 12
Dependent Claim
52 words
A process for the immunological detection of cancer in human tissue or cell specimens comprising: contacting specimens with antibody characterized by binding specificity to nucleolar antigen p120 and detecting the localization of said antibody in the nucleoli of malignant cells but not normal cells of said specimen as a measure of cancer.
Claim 13
Dependent Claim
33 words
A diagnostic kit for performing immunoassays for detecting the presence of nucleolar antigen p120 which comprises multiple containers wherein one of said containers has therein antibody having binding specificity to nucleolar antigen p120.
Claim 14
Dependent Claim
33 words
A diagnostic kit for performing immunoassays for detecting the presence of nucleolar antigen p120 which comprises multiple containers wherein one of said containers has therein antibody having binding specificity to nucleolar antigen p120.
Claim 15
Dependent Claim
11 words
The diagnostic kit of claim 9 wherein the antibody is antisera.
Claim 16
Dependent Claim
13 words
The diagnostic kit of claim 9 wherein the antibody is a monoclonal antibody.
Claim 17
Dependent Claim
20 words
The diagnostic kit of claim 9 wherein the antibody is monoclonal antibody derived from hybridoma clone, ATCC HB 9346 deposit.
Claim 18
Dependent Claim
14 words
The diagnostic kit of claim 9 wherein the antibody is conjugated with a label.
References Cited (Backward Citations)
US4448890A
Cited
US4725669A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-02-19 | 1993-08-21 | 1994-02-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-02-19 | 1997-08-21 | 1998-02-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-02-19 | 2001-08-21 | 2002-02-20 | $7700.00 | Window Closed / Lapsed |